On Monday, Zoe’s Kitchen Inc(NYSE:ZOES)’s shares inclined 0.20% to $34.54.
Zoe’s Kitchen Inc (ZOES) stated financial results for the sixteen weeks ended April 20, 2015.
Highlights for the sixteen weeks ended April 20, 2015, as contrast to the sixteen weeks ended April 21, 2014:
- Total revenue raised 36.2% to $63.0 million.
- Comparable restaurant sales raised 7.7%.
- Opened 12 Company-owned restaurants.
- Restaurant contribution raised 46.2% to $13.7 million.
- Adjusted EBITDA* raised 76.8% to $6.8 million.
- Net income was $0.7 million, or $0.04 per diluted share, contrast to net loss of $10.0 million, or $0.76 per diluted share.
- Adjusted net income* was $0.8 million, or $0.04 per diluted share, contrast to adjusted net loss of $0.4 million or $0.02 per diluted share.
First Quarter 2015 Financial Results
Total revenue, which comprises restaurant sales from Company-owned restaurants and royalty fees, raised 36.2% to $63.0 million in the sixteen weeks ended April 20, 2015, from $46.3 million in the sixteen weeks ended April 21, 2014. Restaurant sales for the sixteen weeks ended April 20, 2015 were $62.9 million, an enhance of 36.5% from $46.1 million in the sixteen weeks ended April 21, 2014.
Comparable restaurant sales raised 7.7% during the sixteen weeks ended April 20, 2015, comprising of a 3.7% enhance in transactions and a 2.8% enhance in product mix, combined with a 1.2% enhance in price. The comparable restaurant base comprises those restaurants open for 18 periods or longer and comprised of 94 restaurants as of April 20, 2015.
Zoe’s Kitchen, Inc., through its auxiliaries, develops and operates fast casual Mediterranean cuisine restaurants in the United States. The company operates a range of restaurant formats, counting in-line, end-cap, and free-standing restaurants.
OmniVision Technologies, Inc.(NASDAQ:OVTI)’s shares dropped -2.41% to $23.90.
OmniVision Technologies, Inc. (OVTI), a leading developer of advanced digital imaging solutions, recently stated financial results for the first quarter of fiscal 2016 that ended on July 31, 2015.
Revenues for the first quarter of fiscal 2016 were $329.9 million, as contrast to $285.9 million in the fourth quarter of fiscal 2015, and $406.5 million in the first quarter of fiscal 2015. GAAP net income in the first quarter of fiscal 2016 was $18.2 million, or $0.31 per diluted share, as contrast to net income of $6.0 million, or $0.10 per diluted share in the fourth quarter of fiscal 2015, and $45.3 million, or $0.78 per diluted share in the first quarter of fiscal 2015. For the first quarter of fiscal 2016, the Company recorded a non-cash tax benefit of $3.1 million, as contrast to $15.1 million for the first quarter of fiscal 2015. These tax benefits reflected the lapses of applicable statute of limitations in certain foreign jurisdictions.
Non-GAAP net income in the first quarter of fiscal 2016 was $28.6 million, or $0.46 per diluted share. Non-GAAP net income in the fourth quarter of fiscal 2015 was $13.9 million, or $0.22 per diluted share. Non-GAAP net income in the first quarter of fiscal 2015 was $54.4 million, or $0.91 per diluted share. Non-GAAP net income excludes stock-based compensation expenses and the related tax effects. Please refer to the attached plan for a reconciliation of GAAP net income to non-GAAP net income for the three months ended July 31, 2015, July 31, 2014 and April 30, 2015.
OmniVision Technologies, Inc. designs, develops, manufactures, and markets semiconductor image-sensor devices worldwide. The company’s principal products comprise CameraChip image sensors, which capture an image electronically and are used in various consumer and commercial mass-market applications; and CameraCubeChip imaging devices that are image sensors with integrated wafer-level optics.
At the end of Monday’s trade, Sarepta Therapeutics Inc (NASDAQ:SRPT)‘s shares dipped -2.7% to $35.70.
Sarepta Therapeutics, Inc.(SRPT), a developer of innovative RNA-targeted therapeutics, recently stated financial results for the three and six months ended June 30, 2015, and offered an update of recent corporate developments.
Financial Results
For the second quarter of 2015, Sarepta stated a non-GAAP net loss of $35.9 million, or $0.87 per share, contrast to a non-GAAP net loss of $24.5 million for the second quarter of 2014, or $0.61 per share. The incremental loss of $11.4 million was primarily the result of raised operating expenses in addition to a decrease in revenue from the Company’s government contracts.
On a GAAP basis, the net loss for the second quarter of 2015 was $41.9 million, or $1.01 per share (counting $5.9 million of stock-based compensation), contrast to a net loss of $33.9 million, or $0.85 per share (counting $5.6 million of stock-based compensation and restructuring expenses) for the second quarter of 2014. The enhance in net loss was primarily due to a decrease of $2.6 million from government contract revenue and enhances of $8.5 million from research and development expenses and $0.7 million from general and administrative expenses. The enhance in operating expenses was primarily due to the timing of manufacturing activities, counting the purchase of raw materials, raised clinical activity in connection with our DMD programs, research and development personnel growth and raised stock compensation expense. These enhances were offset by a decrease of $3.8 million from a loss on change in warrant valuation as all warrants were exercised or expired during 2014.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Platform Specialty Products Corp (NYSE:PAH), ended its Monday’s trading session with -0.10% loss, and closed at $19.12.
Platform Specialty Products Corporation (PAH) a global, diversified specialty chemicals company, declared its financial results for the three and six months ended June 30, 2015.
For the three months ended June 30, 2015:
- Net sales for the second quarter 2015 were $675 million, an enhance of 257% contrast to $189 million in the second quarter of 2014.
- Performance Applications segment: Sales were $182 million, a decline of 4.0% from $189 million in the second quarter of 2014. On a constant currency basis, sales for this segment grew 4.5%.
- Agricultural Solutions segment: Sales were $494 million, a 17.2% decline from $596 million of pro forma as adjusted sales in the second quarter of 2014. On a constant currency basis, pro forma as adjusted sales grew 1.9%.
- Total constant currency sales for the quarter were $690 million, an enhance of 2.5% from second quarter 2014 pro forma constant currency sales of $672 million.
- Adjusted EBITDA for the second quarter 2015 was $168 million, an enhance of 248% contrast to $48 million from the year-preceding period.
Platform Specialty Products Corporation produces and sells specialty chemical products in the Americas, Asia, and Europe. The company’s Performance Materials segment manufactures and markets plating products that are used to plate holes; final finishes, which are used on printed circuit boards; circuit formation products to promote adhesion and form circuit patterns; oxides that are used in the fabrication of multilayer circuit boards; and pre-treatment and cleaning solutions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
